Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Average Rating of “Buy” from Analysts

Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) have received an average rating of “Buy” from the seventeen brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, twelve have assigned a buy recommendation and four have assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $56.2143.

Several research analysts recently commented on the stock. Wedbush reiterated an “outperform” rating and issued a $58.00 target price on shares of Scholar Rock in a report on Tuesday, July 21st. Barclays upped their price target on shares of Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, May 8th. HC Wainwright raised their price target on Scholar Rock from $58.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, June 18th. Finally, Canaccord Genuity Group started coverage on Scholar Rock in a research report on Monday, April 20th. They set a “buy” rating and a $62.00 price objective for the company.

Scholar Rock Stock Down 0.1%

Shares of Scholar Rock stock opened at $48.99 on Friday. Scholar Rock has a 12-month low of $27.07 and a 12-month high of $58.49. The company has a quick ratio of 8.64, a current ratio of 8.64 and a debt-to-equity ratio of 0.71. The stock has a 50 day moving average price of $50.12 and a two-hundred day moving average price of $47.70. The stock has a market capitalization of $5.87 billion, a P/E ratio of -13.65 and a beta of 0.67.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same quarter in the prior year, the company earned ($0.67) EPS. Equities analysts expect that Scholar Rock will post -3.23 earnings per share for the current year.

Insider Transactions at Scholar Rock

In other news, Director Kristina Burow sold 3,053 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.74, for a total transaction of $164,068.22. Following the transaction, the director owned 114,657 shares in the company, valued at approximately $6,161,667.18. The trade was a 2.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael Gilman sold 2,544 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.87, for a total transaction of $137,045.28. Following the transaction, the director directly owned 59,511 shares of the company’s stock, valued at $3,205,857.57. This represents a 4.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 17,149 shares of company stock worth $923,108. Insiders own 10.30% of the company’s stock.

Institutional Investors Weigh In On Scholar Rock

Several hedge funds have recently made changes to their positions in SRRK. Siren L.L.C. raised its holdings in Scholar Rock by 17.0% in the 4th quarter. Siren L.L.C. now owns 10,825,013 shares of the company’s stock valued at $476,842,000 after acquiring an additional 1,575,008 shares in the last quarter. Redmile Group LLC lifted its position in shares of Scholar Rock by 73.7% in the 1st quarter. Redmile Group LLC now owns 9,066,621 shares of the company’s stock worth $445,715,000 after acquiring an additional 3,845,775 shares during the period. Wellington Management Group LLP grew its holdings in shares of Scholar Rock by 26.7% during the 4th quarter. Wellington Management Group LLP now owns 5,759,428 shares of the company’s stock worth $253,703,000 after purchasing an additional 1,213,541 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Scholar Rock by 5.7% during the 4th quarter. Vanguard Group Inc. now owns 5,195,465 shares of the company’s stock worth $228,860,000 after purchasing an additional 280,538 shares in the last quarter. Finally, State Street Corp increased its position in shares of Scholar Rock by 7.2% during the fourth quarter. State Street Corp now owns 4,034,434 shares of the company’s stock valued at $177,717,000 after purchasing an additional 271,331 shares during the period. Institutional investors own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).